Novogen Signs Spanish Patent License With Laboratorios Casen-Fleet
June 23 2008 - 8:00AM
Marketwired
STAMFORD, CT and SYDNEY, AUSTRALIA (NASDAQ: NVGN), the
registered owner of the European Patent "Use of isoflavone
phyto-oestrogen extracts of soy or clover (EPO 656786 B1), has
reached an Agreement with Laboratorios Casen-Fleet for a license in
Spain to the Novogen Patent.
Laboratorios Casen-Fleet, the Spanish affiliate of the US
multinational healthcare company Fleet Laboratories, has recently
acquired the red clover isoflavone-based menopause product Fitogyn
from Laboratorios Gynea S.A. In conjunction with the product
acquisition Laboratorios Casen Fleet and Novogen have agreed on
confidential terms for a Patent License Agreement.
The Chief Executive of Novogen, Mr. Christopher Naughton, said
Novogen was dedicated to the development of isoflavonoid
technology, protected by intellectual property, in both the dietary
supplement and prescription pharmaceutical arenas. In Europe
Novogen has negotiated Patent License Agreements with Laboratorios
Casen-Fleet and Melbrosin International (manufacturer of
Menoflavon).
Novogen's patented dietary supplement products are Promensil,
for women's health including the relief of menopausal symptoms, and
Trinovin, for prostate health. These brands are marketed directly
by Novogen in Australia, Canada and UK, and under license to
distributors in the USA, Europe, South East Asia and South
Africa.
"Since 2005 Novogen has successfully enforced its isoflavone
patent portfolio against USA companies such as GNC, NBTY Inc.,
Natural Alternatives International Inc, Swanson Health Products and
Chattem Inc and Canadian companies such as Swiss Herbal, Sante
Naturelle and Genuine Health," said Mr. Naughton.
About Novogen
Novogen Limited is an Australian biotechnology company that has
patented isoflavone technology for the treatment and prevention of
degenerative diseases and disorders. Over the past ten years,
Novogen has conducted the largest and most comprehensive isoflavone
clinical testing programs in the world. Novogen is involved in drug
discovery and product development for disorders that are commonly
associated with aging and coordinates an international clinical
research and development program with external collaborators,
hospitals and universities.
Novogen's investigational anti-cancer drug phenoxodiol is
currently in Phase III human clinical trials in the US, Europe and
Australia. The rights to commercialise this drug are licensed to
the Company's majority owned subsidiary, Marshall Edwards, Inc.,
(NASDAQ: MSHL). More information can be found at www.novogen.com
and www.marshalledwardsinc.com.
Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
FOR FURTHER INFORMATION: CHRISTOPHER NAUGHTON MANAGING DIRECTOR
NOVOGEN LIMITED TEL 011 61 2 9878 0088 http://www.novogen.com
ISSUED BY: WHITECOAT STRATEGIES CONTACT: DAVID SHEON 202
470-2880
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024